Omalizumab in the real-world: systematic review of asthma control outcomes reported by patients

Abstract

Background: The efficacy of omalizumab on patient-reported outcomes (PROs) in severe allergic asthma has been reported in several randomised controlled trials. This systematic literature review aimed to summarise the effectiveness of omalizumab on PROs in real-world settings Methods: The literature search was performed using PubMed, EMBASE and Cochrane databases. It included studies using Global Evaluation of Treatment Effectiveness (GETE), Asthma Quality of Life Questionnaire (AQLQ), Asthma Control Test (ACT) and Asthma Control Questionnaire (ACQ) comparing 16 weeks, 6 months, 12 months, and end of the study post-treatment outcomes with baseline observations in patients with severe allergic asthma Results: In total, 85 studies were included in this systematic review. GETE scores were consistently good or excellent in 53%–100% of patients receiving omalizumab across time points compared with baseline. Omalizumab treatment also improved health-related quality of life (HRQoL) and asthma control scores at all time points (Table). At the end of the studies, the proportion of participants who achieved minimal clinically important differences (MCID) for ACT (≥3), ACQ (≥0.5) and AQLQ (≥0.5) ranges from 50%–62%, 60%–95% and 72%–100%, respectively Conclusion: Omalizumab treatment consistently improves asthma-related HRQoL (AQLQ), asthma control (ACQ, ACT), physicians’/patients’ GETE in real-world treatment of severe allergic asthma